Genomma Lab Internacional. de Valuation

Q: What is the Fair Price of LAB B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

LAB B (MX$18.82) is trading below our estimate of [[fair value]] (MX$21.54)

Is LAB B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LAB B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: LAB B (MX$18.82) is trading below our estimate of fair value (MX$21.54)

Significantly Below Fair Value: LAB B is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LAB B?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for LAB B. This is calculated by dividing LAB B's market cap by their current preferred multiple.
What is LAB B's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	Mex$17.88b

LAB B key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.4x
Enterprise Value/EBITDA	6.3x
PEG Ratio	0.7x

Price to Earnings Ratio vs Peers

How does LAB B's PE Ratio compare to its peers?

The above table shows the PE ratio for LAB B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	31.7x
MEGA Mega Lifesciences	16.6x	11.8%	฿33.1b
000650 Renhe PharmacyLtd	13.7x	n/a	CN¥7.4b
500126 Procter & Gamble Health	43.1x	n/a	₹86.2b
BLUEJET Blue Jet Healthcare	53.5x	25.6%	₹84.6b
LAB B Genomma Lab Internacional. de	13.5x	19.4%	Mex$17.9b

Price-To-Earnings vs Peers: LAB B is good value based on its Price-To-Earnings Ratio (13.5x) compared to the peer average (31.7x).

Price to Earnings Ratio vs Industry

How does LAB B's PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	19.3%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	19.3%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: LAB B is good value based on its Price-To-Earnings Ratio (13.5x) compared to the Global Pharmaceuticals industry average (23.8x).

Price to Earnings Ratio vs Fair Ratio

What is LAB B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LAB B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	13.5x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate LAB B's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst LAB B forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	Mex$18.82	Mex$20.00 +6.3%	16.0%	Mex$26.00	Mex$16.00	n/a	7
Aug ’25	Mex$18.69	Mex$20.00 +7.0%	16.0%	Mex$26.00	Mex$16.00	n/a	7
Jul ’25	Mex$17.03	Mex$19.50 +14.5%	15.6%	Mex$25.00	Mex$16.00	n/a	6
Jun ’25	Mex$17.77	Mex$19.46 +9.5%	14.5%	Mex$25.00	Mex$16.00	n/a	7
May ’25	Mex$16.71	Mex$19.46 +16.4%	14.5%	Mex$25.00	Mex$16.00	n/a	7
Apr ’25	Mex$15.33	Mex$21.03 +37.2%	12.4%	Mex$25.00	Mex$18.00	n/a	7
Mar ’25	Mex$13.78	Mex$21.03 +52.6%	12.4%	Mex$25.00	Mex$18.00	n/a	7
Feb ’25	Mex$14.12	Mex$21.87 +54.9%	12.1%	Mex$25.00	Mex$18.00	n/a	6
Jan ’25	Mex$14.16	Mex$21.87 +54.4%	12.1%	Mex$25.00	Mex$18.00	n/a	6
Dec ’24	Mex$14.18	Mex$21.87 +54.2%	12.1%	Mex$25.00	Mex$18.00	n/a	6
Nov ’24	Mex$13.55	Mex$21.97 +62.1%	11.6%	Mex$25.00	Mex$18.00	n/a	6
Oct ’24	Mex$13.41	Mex$20.83 +55.3%	15.1%	Mex$25.00	Mex$17.00	n/a	7
Sep ’24	Mex$14.04	Mex$21.24 +51.3%	14.9%	Mex$25.00	Mex$17.00	n/a	7
Aug ’24	Mex$14.52	Mex$21.10 +45.3%	14.3%	Mex$24.00	Mex$17.00	Mex$18.69	7
Jul ’24	Mex$13.20	Mex$21.67 +64.2%	11.1%	Mex$24.00	Mex$18.00	Mex$17.03	7
Jun ’24	Mex$15.07	Mex$21.67 +43.8%	11.1%	Mex$24.00	Mex$18.00	Mex$17.77	7
May ’24	Mex$14.94	Mex$21.67 +45.1%	11.1%	Mex$24.00	Mex$18.00	Mex$16.71	7
Apr ’24	Mex$14.49	Mex$21.67 +49.6%	11.1%	Mex$24.00	Mex$18.00	Mex$15.33	7
Mar ’24	Mex$14.40	Mex$22.78 +58.2%	10.6%	Mex$26.00	Mex$18.00	Mex$13.78	6
Feb ’24	Mex$18.42	Mex$23.12 +25.5%	11.0%	Mex$26.00	Mex$18.00	Mex$14.12	6
Jan ’24	Mex$16.94	Mex$23.58 +39.2%	11.4%	Mex$26.00	Mex$18.00	Mex$14.16	6
Dec ’23	Mex$16.06	Mex$24.36 +51.7%	12.8%	Mex$29.00	Mex$18.00	Mex$14.18	7
Nov ’23	Mex$15.69	Mex$24.36 +55.2%	12.8%	Mex$29.00	Mex$18.00	Mex$13.55	7
Oct ’23	Mex$13.84	Mex$25.25 +82.4%	14.6%	Mex$31.00	Mex$18.00	Mex$13.41	8
Sep ’23	Mex$16.17	Mex$26.23 +62.2%	9.9%	Mex$31.00	Mex$22.00	Mex$14.04	8
Aug ’23	Mex$18.37	Mex$26.23 +42.8%	9.9%	Mex$31.00	Mex$22.00	Mex$14.52	8

Analyst Forecast: Target price is less than 20% higher than the current share price.